U3 Pharma AG raised €27 million (US$34.7 million) to accelerate development of its pipeline of targeted therapies, designed to modulate signal transduction pathways in cancer. (BioWorld International)
U3 Pharma AG raised €27 million (US$34.7 million) to accelerate development of its pipeline of targeted therapies, designed to modulate signal transduction pathways in cancer. (BioWorld International)
